CBT
NTLA icon

Capital Bank & Trust’s Intellia Therapeutics NTLA Stock Holding History

Capital Bank & Trust’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27
Closed -$1K – 792
2018
Q3 		$1K Hold
27
– – ﹤0.01% 792
2018
Q2 		$1K Hold
27
– – ﹤0.01% 669
2018
Q1 		$1K Hold
27
– – ﹤0.01% 636
2017
Q4 		$1K Buy
+27
New +$623 ﹤0.01% 679

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Capital Bank & Trust's NTLA Position: Q4 2018 in Review

Capital Bank & Trust sold out of Intellia Therapeutics (NTLA) in Q4 2018, closing a stake of 27 shares — an estimated $1K sold.

Capital Bank & Trust first reported a position in NTLA in Q4 2017 and held it in 4 quarters. The position peaked at $1K in Q3 2018. 141 funds tracked by Wall St. Rank hold NTLA as of Q4 2018.

  • Capital Bank & Trust reported no remaining Intellia Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Capital Bank & Trust sold 27 Intellia Therapeutics shares in Q4 2018, an estimated $1K.
  • Capital Bank & Trust first reported a position in Intellia Therapeutics in Q4 2017 and held it in 4 quarters.
  • Capital Bank & Trust's Intellia Therapeutics position peaked at $1K in Q3 2018.
  • 141 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2018.

Based on Capital Bank & Trust's 13F filing for Q4 2018, filed 14 Feb 2019.